[{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cetylsalicylic Acid","moa":"COX-1\/COX-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"CNIC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"||Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ferrer Internacional \/ CNIC","highestDevelopmentStatusID":"15","companyTruncated":"Ferrer Internacional \/ CNIC"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ozenoxacin","moa":"DNA gyrase | DNA topoisomerase IV | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ozenoxacin","moa":"DNA gyrase | DNA topoisomerase IV | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Prilenia therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.56999999999999995,"dosageForm":"Capsule","sponsorNew":"Ferrer Internacional \/ Grupo Ferrer Internacional","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Grupo Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Arasertaconazole Nitrate","moa":"Ergosterol synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pessary","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Axonal-Biostatem","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Gelatin Tannate","moa":"Gastrointestinal mucosa","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ferrer Internacional \/ Axonal-Biostatem","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Axonal-Biostatem"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ciclopirox","moa":"Iron | Aluminium","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Ferrer Internacional","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MEXICO","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Racecadotril","moa":"Neprilysin","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Asceneuron","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"ASN90","moa":"OGA","graph1":"Neurology","graph2":"Phase I","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Verge Genomics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Ferrer Internacional","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"11","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"15","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"15","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Treeway","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferrer Internacional \/ Treeway","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Treeway"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Ferrer Internacional","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Epa Supplement","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Ferrer Internacional","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Ferrer Internacional"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Histocell","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"FAB117-HC","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Histocell","highestDevelopmentStatusID":"7","companyTruncated":"Ferrer Internacional \/ Histocell"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Julius Clinical | TRICALS Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"FAB122","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Julius Clinical | TRICALS Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Julius Clinical | TRICALS Foundation"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FAB122","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"FNP-223","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"FNP-223","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"FNP-223","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Undisclosed"}]
	
		
			
Find Clinical Drug Pipeline Developments & Deals by Ferrer Internacional 
		
	 
	
	
		
								
						
					
					
						
					
							
				
									
						
							
															
									Filters
										 
									
										× 
										FILTER:
										
																									
															
																Company Name 
																															
															
														 
																												
															Year  
															
														 
																												
															DEALS // DEV. 
															
														 
																												
															Country 
															
														 
																												
															
																Sponsor 
																															
															
														 
																												
															Therapeutic Area 
															
														 
																												
															Study Phase 
															
														 
																												
															Deal Type 
															
														 
																												
															Product Type 
															
														 
																												
															Dosage Form 
															
														 
																												
															Lead Product 
															
														 
																												
															Target